~~<i id='30DE3C0633'><strike id='30DE3C0633'><tt id='30DE3C0633'><pre id='30DE3C0633'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：knowledge 2025-09-27 12:23:08 - browse：41475

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Roche drug slashes death risk in early

focus

entertainment

focus

leisure time

explore

Wikipedia

AtESMO2023,antibody-drugconjugateswerefeaturedprominently.AndrewJoseph/STATMADRID—Ifyouhadtopinpoint

WSS

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Health tech investors get more selective as pandemic boom fades

Health tech investors get more selective as pandemic boom fades

Is there really a nursing shortage in the U.S.?

STAT Summit: The economic case for universal basic health care

hotspot

knowledge

focus

Affirmative action in medical school literally saved lives

Biden announces an advanced cancer research initiative

What does generative AI mean for health care? We asked experts

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

Drug repurposing or repositioning? The language matters

An outrageous hospital charge: I paid $710 for an hour of babysitting

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Study on Amgen’s bispecific immunotherapy produces positive data

Bright Health sells Medicare Advantage business to Molina

Roche drug slashes death risk in early

entertainment

Results on Novartis prostate cancer therapy could expand its use

Results on Novartis prostate cancer therapy could expand its use

Why a market frenzy over new weight loss drugs defies logic

Roche acquires Telavant from Roivant, adding experimental IBD treatment

VC firm RA Capital starts a new synthetic biology incubator

As the dark side of IVF slowly comes into focus, even more transparency is needed

focus

leisure time

explore

Wikipedia